TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24731783

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment after 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no natalizumab treatment)
Number of subjects: 60
Study: 23525453

Group type: EXPERIMENTAL
Intervention: Intrapleural bevacizumab (300 mg) with cisplatin (30 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intrapleural cisplatin (30 mg) alone
Number of subjects: 72
Study: 19826855

Group type: EXPERIMENTAL
Intervention: Social skills and neurocognitive individualized training (SSANIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Structured leisure activities (SLA)
Number of subjects: 60
Study: 18568412

Group type: EXPERIMENTAL
Intervention: Magnesium citrate (610 mg orally every other day for 2 months)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Calcium acetate therapy (control group)
Number of subjects: 47
Study: 16622610

Group type: EXPERIMENTAL
Intervention: Immediate PCI within 2 hours
Number of subjects: 451

Group type: COMPARATOR
Intervention: Delayed PCI after 12-72 hours
Number of subjects: 451
Study: 12901032

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both COX‐2 inhibitors
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 16
Study: 11218488

Group type: EXPERIMENTAL
Intervention: Composite inlays (Tetric, blend‐a‐lux, Pertac)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ceramic inlays (Empress)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Inlays in small cavities
Number of subjects: 71

Group type: COMPARATOR
Intervention: Molar inlays
Number of subjects: 71
Study: 8972810

Group type: EXPERIMENTAL
Intervention: Rota‐dent (Rota‐dent, Kusnacht, Switzerland)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Plaque Remover (Braun/Oral‐B, Kronberg, Germany)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Interplak (Bausch & Lomb, Berlin, Germany)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Manual technique (normal toothbrush, interdental brush, dental floss)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All electric toothbrushes
Number of subjects: 38
Study: 1281177

Group type: EXPERIMENTAL
Intervention: Allergen challenge in allergic patients
Number of subjects: 24
Study: 6084675

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g 1 h pre‐operatively and every 6 h for 48 h (vein graft patients)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (vein graft patients)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g (synthetic graft patients)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g (synthetic graft patients)
Number of subjects: 140
Study: 29266047

Group type: EXPERIMENTAL
Intervention: Sensory feedback (acoustic/vibration) for face-down positioning after macular hole surgery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sensory feedback (acoustic/vibration) for side positioning after retinal detachment surgery
Number of subjects: 48

Group type: COMPARATOR
Intervention: Instructional methods (verbal/illustrated)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Questionnaires regarding sensor acceptance
Number of subjects: 48
Study: 29159993

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 110

Group type: COMPARATOR
Intervention: General dietary advice (GDA)
Number of subjects: 110
Study: 27687379

Group type: EXPERIMENTAL
Intervention: Air-Qsp (Group A: n = 20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: i-Gel (Group I: n = 17)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Air-Qsp (Group A)
Number of subjects: 37

Group type: COMPARATOR
Intervention: i-Gel (Group I)
Number of subjects: 37
Study: 24315706

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) - five walking sessions per week at 55‐100% of peak oxygen uptake (VO2peak) for 30‐60 min per session
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 50
Study: 23424961

Group type: EXPERIMENTAL
Intervention: Fluoxetine (Flu) 20 mg/day
Number of subjects: 18
Study: 20473992

Group type: EXPERIMENTAL
Intervention: RFA (VNUS ClosureFAST)
Number of subjects: 131

Group type: COMPARATOR
Intervention: EVLA (980 nm)
Number of subjects: 131
Study: 18384551

Group type: EXPERIMENTAL
Intervention: Nicotine patch (7 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 24

Group type: COMPARATOR
Intervention: No patch
Number of subjects: 24
Study: 16181170

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention by an expert physical/occupational therapist
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 84
Study: 14623733

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10674566

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide (400 microg) once daily for 4 weeks
Number of subjects: 242

Group type: COMPARATOR
Intervention: Aqueous spray (256 microg) once daily for 4 weeks
Number of subjects: 242
Study: 8961989

Group type: EXPERIMENTAL
Intervention: Surgery preceded by 40 Gy radiotherapy (20 fractions of 2 Gy over 4 weeks)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Surgery preceded by 40 Gy radiotherapy
Number of subjects: 279
Study: 1553856

Group type: EXPERIMENTAL
Intervention: 3.125 mg intravenous (IV) prochlorperazine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 mg oral prochlorperazine
Number of subjects: 6
Study: 3857405

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (Cp) injections, both intradermal (i.c.) and subcutaneous (s.c.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (Cp) injections
Number of subjects: 0
Study: 28984157

Group type: EXPERIMENTAL
Intervention: BADI intervention
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: BADI intervention with therapist support
Number of subjects: 1077
Study: 27035371

Group type: EXPERIMENTAL
Intervention: Formula containing Lactobacillus reuteri DSM 17938 (CLr)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control formula (CCt)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Formula containing Lactobacillus reuteri DSM 17938 (VLr)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control formula (VCt)
Number of subjects: 40
Study: 23909409

Group type: EXPERIMENTAL
Intervention: Alitretinoin (30 mg oral dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy controls (30 mg oral dose of alitretinoin)
Number of subjects: 8
Study: 22449647

Group type: EXPERIMENTAL
Intervention: Hitkashrut co-parent training program
Number of subjects: 209

Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 209
Study: 19889036

Group type: EXPERIMENTAL
Intervention: Modified Symptom Severity Index (SSI)
Number of subjects: 108
Study: 18672768

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 90

Group type: COMPARATOR
Intervention: Somiton tablet (Control)
Number of subjects: 90
Study: 16204431

Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg at 9:00 AM, 1:00 PM, and 6:00 PM after 5 days of abstinence from caffeine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Caffeine 300 mg/day and 600 mg/day for 5 days prior to challenge
Number of subjects: 96

Group type: COMPARATOR
Intervention: Caffeine 0 mg (control)
Number of subjects: 96
Study: 15984440

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX)
Number of subjects: 0
Study: 12403222

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy at 20 ppm weaned to 5 ppm over 24-48 hours
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no iNO therapy)
Number of subjects: 34
Study: 10464845

Group type: EXPERIMENTAL
Intervention: HFA‐134a BDP, 1600 mg total dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFC‐11/12 BDP, 2000 mg total dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: HFA‐134a placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFC‐11/12 placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HFA‐134a BDP
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFC‐11/12 BDP
Number of subjects: 0
Study: 7790534

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate (CHX) rinse for 1 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate (CHX) irrigation for 15 s
Number of subjects: 24

Group type: COMPARATOR
Intervention: saline rinse for 1 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: saline irrigation for 15 s
Number of subjects: 24
Study: 2284328

Group type: EXPERIMENTAL
Intervention: 600 mg naftidrofuryl daily per os
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 6776569

Group type: EXPERIMENTAL
Intervention: Butoctamide hydrogen succinate (600 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (linolenic acid)
Number of subjects: 6
Study: 6419633

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam i.m.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg midazolam i.m.
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.2 mg/kg diazepam i.m.
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 mg/50 mg pethidine/promethazine i.m.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo i.m.
Number of subjects: 10
Study: 30010085

Group type: EXPERIMENTAL
Intervention: Video decision aid
Number of subjects: 516

Group type: COMPARATOR
Intervention: Standard educational materials
Number of subjects: 516
Study: 24855313

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Psychoeducational (PED)
Number of subjects: 67
Study: 24924849

Group type: EXPERIMENTAL
Intervention: Distractor-response execution resistance (ER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distractor-repeat trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practice effect on error protection
Number of subjects: 0
Study: 22040838

Group type: EXPERIMENTAL
Intervention: Exercise training with placebo (EP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise training with metformin (EM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2,000 mg/day metformin (M)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 32
Study: 20833613

Group type: EXPERIMENTAL
Intervention: AAR counseling at community pharmacies
Number of subjects: 24
Study: 18180434

Group type: EXPERIMENTAL
Intervention: Methylphenidate OROS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15823456

Group type: EXPERIMENTAL
Intervention: Meter A
Number of subjects: 409

Group type: COMPARATOR
Intervention: Meter B
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Meter C
Number of subjects: 409
Study: 12839321

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10664640

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.0 and 2.0 g/d of elemental calcium)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 8793045

Group type: EXPERIMENTAL
Intervention: 1% fat cow's milk
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Soy-based nondairy drink
Number of subjects: 30
Study: 1616164

Group type: COMPARATOR
Intervention: Normal saline solution, 10 mL epidurally and 3 mL intramuscularly (IM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 10 mL of epidural saline solution and 75 mg (3 mL) of diclofenac IM
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2 mg of morphine in 10 mL of epidural saline solution and 3 mL of saline solution IM
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2 mg of morphine in 10 mL of epidural saline solution and 75 mg of diclofenac IM
Number of subjects: 120
Study: 6717874

Group type: EXPERIMENTAL
Intervention: Intervention management with oxytocin if labor did not ensue within 12 hours of rupture of membranes
Number of subjects: 134

Group type: COMPARATOR
Intervention: Expectant management (bed rest and observation)
Number of subjects: 134
Study: 31141291

Group type: EXPERIMENTAL
Intervention: Dynamic navigation system for implant placement
Number of subjects: 14
Study: 29314505

Group type: EXPERIMENTAL
Intervention: Home monitoring of BNP
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Moving average filter (fBNP)
Number of subjects: 107
Study: 27050177

Group type: EXPERIMENTAL
Intervention: 15ml natural honey applied on oral mucosa
Number of subjects: 28

Group type: COMPARATOR
Intervention: 15ml plain water applied on oral mucosa (Control)
Number of subjects: 28
Study: 25185289

Group type: EXPERIMENTAL
Intervention: Allergopharma group
Number of subjects: 9233

Group type: COMPARATOR
Intervention: Alutard‐SQ group
Number of subjects: 9233
Study: 22793964

Group type: EXPERIMENTAL
Intervention: Group I (RE maintained between 45 and 59)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group II (RE maintained between 30 and 44)
Number of subjects: 20
Study: 19523697

Group type: EXPERIMENTAL
Intervention: Geriatric ward management
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard care management
Number of subjects: 45
Study: 19023841

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention using urinary cotinine as an abstinence indicator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily immunoassay test strips for urinary cotinine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily multiple CO measurements
Number of subjects: 0
Study: 15841628

Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch (30-minute application)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (30-minute application)
Number of subjects: 79
Study: 12001006

Group type: EXPERIMENTAL
Intervention: Metronidazole 1% cream with sunscreen SPF 15
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (vehicle containing sunscreen with SPF 15)
Number of subjects: 120
Study: 10367603

Group type: EXPERIMENTAL
Intervention: Depressed smokers
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control smokers
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control non-smokers
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Depressed non-smokers
Number of subjects: 245
Study: 8652857

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Combination of Interferon-alpha and Hydroxyurea
Number of subjects: 649
Study: 1793694

Group type: EXPERIMENTAL
Intervention: Post-operative autotransfusion with pre-operative aspirin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Post-operative autotransfusion without pre-operative aspirin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (donor blood only)
Number of subjects: 21
Study: 6629620

Group type: EXPERIMENTAL
Intervention: Endurance fitness programme (1 1/4 hours per day)
Number of subjects: 716

Group type: COMPARATOR
Intervention: Skill programme
Number of subjects: 716

Group type: COMPARATOR
Intervention: Previous physical education programme (controls)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Physical activity programme (after phase one)
Number of subjects: 716

Group type: COMPARATOR
Intervention: Formal teaching time loss (45-60 minutes)
Number of subjects: 716
Study: 29532983

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) target (<120 mm Hg)
Number of subjects: 5425

Group type: COMPARATOR
Intervention: Standard systolic blood pressure (SBP) target (<140 mm Hg)
Number of subjects: 5425
Study: 27612499

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 281

Group type: COMPARATOR
Intervention: No Diabetes Mellitus (non-DM)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Baseline Rutherford category
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) >1.4
Number of subjects: 281
Study: 25708818

Group type: EXPERIMENTAL
Intervention: Total facial nerve decompression (surgery group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Prednisolone treatment (control group)
Number of subjects: 15
Study: 22948805

Group type: EXPERIMENTAL
Intervention: Endocervical curettage (ECC)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Endocervical brushing (EB)
Number of subjects: 208
Study: 20110339

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study: 18205045

Group type: EXPERIMENTAL
Intervention: 3-year disease-free survival (DFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DFS at 2 or 3 years
Number of subjects: 0
Study: 15665717

Group type: EXPERIMENTAL
Intervention: DT-pertussis toxoid
Number of subjects: 0

Group type: COMPARATOR
Intervention: DT
Number of subjects: 0
Study: 14500176

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine with sevoflurane anesthesia (Group 1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with sevoflurane anesthesia (Group 2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both groups (0.5% and 1% lidocaine)
Number of subjects: 35
Study: 10383546

Group type: EXPERIMENTAL
Intervention: WAG 994 1 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 8558223

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN alpha-2b) administered at 20 MU/m2/d intravenously for 1 month and 10 MU/m2 three times per week subcutaneously for 48 weeks
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN alpha-2b)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 287
Study: 1828765

Group type: EXPERIMENTAL
Intervention: Procaterol (20 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 20
Study: 6348227

Group type: EXPERIMENTAL
Intervention: Single dose of amikacin 7.5 mg/kg intramuscularly
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sulfisoxazole 150 mg/kg/day orally for 10 days
Number of subjects: 54
Study: 30586730

Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study: 29589490

Group type: EXPERIMENTAL
Intervention: Baseline factors associated with lower physical HRQL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline factors associated with mental HRQL, hip function, and health utility
Number of subjects: 0
Study: 25956926

Group type: EXPERIMENTAL
Intervention: Combined physical activity and fall prevention intervention enhanced with health coaching and pedometers
Number of subjects: 130

Group type: COMPARATOR
Intervention: Advice brochure (control group)
Number of subjects: 130
Study: 24114811

Group type: EXPERIMENTAL
Intervention: AG013 (oral rinse containing recombinant Lactococcus lactis secreting hTFF1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AG013
Number of subjects: 25

Group type: COMPARATOR
Intervention: AG013 or placebo
Number of subjects: 25
Study: 21671743

Group type: COMPARATOR
Intervention: Neural correlates of autobiographical memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neural correlates of episodic memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neural correlates of semantic memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 19349543

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP) - irinotecan 60 mg/m² on days 1, 8, and 15; cisplatin 60 mg/m² day 1, every 4 weeks
Number of subjects: 651

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP) - etoposide 100 mg/m² on days 1 through 3; cisplatin 80 mg/m² day 1, every 3 weeks
Number of subjects: 651
Study: 17250718

Group type: EXPERIMENTAL
Intervention: Healthy young subjects
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Healthy old subjects
Number of subjects: 90

Group type: COMPARATOR
Intervention: Old subjects with vascular risk factors
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Healthy young and old subjects
Number of subjects: 90
Study: 15479311

Group type: EXPERIMENTAL
Intervention: Target-controlled propofol infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual propofol infusion
Number of subjects: 50
Study: 11528490

Group type: EXPERIMENTAL
Intervention: Oral dose of iodized oil, containing 540 mg I
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 11367648

Group type: EXPERIMENTAL
Intervention: Xinmaitong (XMT) capsule
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional western medical therapy
Number of subjects: 38
Study: 7583724

Group type: EXPERIMENTAL
Intervention: Helical CT with monophasic injections of contrast agent at 3 mL/second
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional CT with biphasic injections at 2 and 0.7 mL/second
Number of subjects: 166
Study: 1976782

Group type: EXPERIMENTAL
Intervention: (+/‐)‐propranolol base (0.108 mg kg‐1 of ideal body weight)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: (+/‐)‐sotalol base (1.06 mg kg‐1 of ideal body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-obese control subjects
Number of subjects: 6
Study: 359625

Group type: EXPERIMENTAL
Intervention: Aqueous terbutaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5 mg)
Number of subjects: 0
Study: 30970057

Group type: EXPERIMENTAL
Intervention: Rosemary-based toothpaste (Group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional toothpaste (Group B)
Number of subjects: 110